-0.60%
-0.93%
-14.48%
-26.06%
0.43%
-46.57%
69.13%
AI Spotlight on BANB
Company Description
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs).It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
The company was founded in 1971 and is headquartered in Bubendorf, Switzerland.Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Market Data
| Last Price | 58.45 |
| Change Percentage | -0.60% |
| Open | 58.8 |
| Previous Close | 58.8 |
| Market Cap ( Millions) | 4382 |
| Volume | 100769 |
| Year High | 91.65 |
| Year Low | 54.7 |
| M A 50 | 61.81 |
| M A 200 | 74.15 |
Financial Ratios
| FCF Yield | -1.15% |
| Dividend Yield | 1.37% |
| ROE | 8.65% |
| Debt / Equity | 0.02% |
| Net Debt / EBIDTA | -37.57% |
| Price To Book | 3.37 |
| Price Earnings Ratio | 38.77 |
| Price To FCF | -87.26 |
| Price To sales | 7.58 |
| EV / EBITDA | 25.99 |
News
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Commercial Active Pharmaceutical Ingredients
Expected Growth : 8.97 %
What the company do ?
Commercial Active Pharmaceutical Ingredients from Bachem Holding AG refers to the production and supply of high-quality APIs for pharmaceutical companies, supporting the development of innovative medicines.
Why we expect these perspectives ?
Strong demand for peptide-based drugs, increasing outsourcing of API manufacturing, and Bachem's leadership in peptide synthesis technology drive the 8.97% growth in Commercial Active Pharmaceutical Ingredients. Additionally, the company's strategic partnerships, capacity expansions, and regulatory approvals for new products contribute to the segment's growth.
Segment n°2 -> Clinical Medicines Category Development
Expected Growth : 9.33 %
What the company do ?
Clinical Medicines Category Development from Bachem Holding AG involves developing and manufacturing peptides and oligonucleotides for pharmaceutical companies, supporting clinical trials and commercialization.
Why we expect these perspectives ?
Bachem Holding AG's Clinical Medicines Category growth of 9.33% is driven by increasing demand for peptide-based medicines, expansion into emerging markets, and strategic partnerships. Additionally, advancements in biotechnology and rising investments in R&D are contributing to the growth. Furthermore, the company's focus on innovative manufacturing processes and cost-effective production methods are also supporting the segment's growth.
Segment n°3 -> Research and Specialties
Expected Growth : 9.27 %
What the company do ?
Bachem Holding AG's Research focuses on peptide chemistry and biotechnology, while its Specialties include custom synthesis, catalog peptides, and pharmaceutical ingredients.
Why we expect these perspectives ?
Bachem Holding AG's Research and Specialties segment growth of 9.27% is driven by increasing demand for peptides and oligonucleotides in pharmaceutical and biotech industries, expansion into new markets, and strategic partnerships. Additionally, investments in R&D and manufacturing capabilities have enhanced efficiency and productivity, contributing to the segment's growth.
Bachem Holding Ag Products
| Product Range | What is it ? |
|---|---|
| Pegylated Peptides | Bachem offers a range of pegylated peptides, which are used in various therapeutic areas, including oncology, inflammatory diseases, and rare genetic disorders. |
| Cancer Vaccines | Bachem develops and manufactures cancer vaccines, which are used to prevent and treat various types of cancer. |
| Cosmetic Peptides | Bachem offers a range of cosmetic peptides, which are used in skincare products to improve skin elasticity, reduce wrinkles, and enhance skin texture. |
| Neuropeptides | Bachem develops and manufactures neuropeptides, which are used to treat various neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression. |
| GMP Peptides | Bachem offers a range of GMP peptides, which are used as active pharmaceutical ingredients (APIs) in various therapeutic areas. |
| Custom Peptide Synthesis | Bachem offers custom peptide synthesis services, which enable researchers and pharmaceutical companies to develop new peptide-based drugs. |
| APIs and Intermediates | Bachem develops and manufactures APIs and intermediates, which are used in the production of pharmaceuticals and biologics. |
Bachem Holding AG's Porter Forces
Threat Of Substitutes
Bachem Holding AG operates in the pharmaceutical industry, where substitutes are limited. However, the company's focus on peptides and oligonucleotides may lead to some substitution risks.
Bargaining Power Of Customers
Bachem Holding AG's customers are primarily pharmaceutical and biotechnology companies, which have limited bargaining power due to the company's specialized products and services.
Bargaining Power Of Suppliers
Bachem Holding AG relies on a few key suppliers for raw materials, which may lead to some bargaining power. However, the company's long-term relationships and diversified supply chain mitigate this risk.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and capital requirements. This limits the threat of new entrants for Bachem Holding AG.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players. Bachem Holding AG faces intense rivalry from companies such as PolyPeptide Group and Sandoz.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.03% |
| Debt Cost | 7.50% |
| Equity Weight | 99.97% |
| Equity Cost | 7.50% |
| WACC | 7.50% |
| Leverage | 0.03% |
Bachem Holding AG : Quality Control
Bachem Holding AG passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DESN.SW | Dottikon Es Holding AG engages in the manufacture and sale of performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical industries worldwide. The company's chemicals and … |
| KEMIRA.HE | Kemira Oyj operates as a chemicals company in Finland, rest of Europe, the Middle East, Africa, the Americas, and the Asia Pacific. It operates in two segments, Pulp & Paper … |
| FPE3.DE | Fuchs Petrolub SE develops, produces, and sells lubricants and related specialties worldwide. It offers engine and gear oils, central hydraulic oils, greases, shock absorber fluids, biodegradable lubricants; brake fluids and … |
| SOLB.BR | Solvay SA provides advanced materials and specialty chemicals worldwide. It operates through four segments: Materials, Chemicals, Solutions, and Corporate & Business Services. The Materials segment offers specialty polymers, including aromatic … |
| SOL.MI | SOL S.p.A. engages in the applied research, production, and marketing of technical and medical gases; and in home medical assistance and related medical equipment in Italy and internationally. The company … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Solvay
A-Score
1-Year Total Return ->
🥈
Kemira
A-Score
1-Year Total Return ->
🥉
Fuchs Petrolub
A-Score
1-Year Total Return ->
4
SOL
A-Score
1-Year Total Return ->
5
Dottikon Es Holding
A-Score
1-Year Total Return ->
6
